Analyst consensus rating
Ironwood Pharmaceuticals Analyst Rating: none
Direct answer
Ironwood Pharmaceuticals's consensus rating is none.
4 analysts are included in the current consensus when a coverage count is available.
The same consensus reports an average price target of $6.10.
Forecast evidence checked September 9, 2026.
Get free Ironwood Pharmaceuticals email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Current price
- $4.17
- Average price target
- $6.10
- High price target
- $10.00
- Low price target
- $3.70
- Low target gap
- -11.3%
- Target upside
- +46.3%
- High target gap
- +139.8%
- Target range width
- 151.1%
- Consensus rating
- none
- Analysts
- 4
- Evidence date
- September 9, 2026
- Valid through
- September 16, 2026
Explore related company data
Read the frequently asked questions.
What is the analyst consensus rating for Ironwood Pharmaceuticals?
Ironwood Pharmaceuticals has a verified none consensus. The same dataset has an average price target of $6.10.
How far are Ironwood Pharmaceuticals's low and high targets from the recorded price?
The low target implies -11.3%, while the high target implies +139.8%.
How many analysts are included in Ironwood Pharmaceuticals's consensus?
The verified consensus includes 4 analysts.
How is Ironwood Pharmaceuticals's target upside or downside calculated?
The average target of $6.10 is divided by the recorded price of $4.17, then one is subtracted to produce +46.3%. This does not guarantee a future return.
When was Ironwood Pharmaceuticals's analyst forecast verified?
The data was verified on 2026-09-09. The dataset is valid through 2026-09-16.